Median Technologies' Eyonis LCS, an AI tool for low-dose CT lung cancer screening, receives FDA clearance.
Key Details
- 1Median Technologies received FDA clearance for Eyonis LCS, an AI/ML-powered computer-aided detection software as a medical device.
- 2Designed to assist in the interpretation of low-dose CT (LDCT) scans for lung cancer screening, addressing inter-reader variability.
- 3Eyonis LCS is reported as the first end-to-end FDA-cleared device specifically for lung cancer screening workflows.
- 4Performance testing showed 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value (NPV).
- 5The tool is aimed at improving screening access and diagnostic accuracy, as well as reducing unnecessary procedures.
Why It Matters
FDA clearance for Eyonis LCS marks a significant advancement in AI-assisted lung cancer screening by leveraging CT imaging. The device's strong performance metrics and focus on workflow efficiency could help radiology practices meet increasing screening demands while improving patient outcomes.
Source
Radiology Business
Related News
•AuntMinnie
AI Triage Tool Speeds Up ICH Head CT Turnaround in ED
AI-based triage for intracranial hemorrhage on head CT reduced emergency department report turnaround by 13 minutes.
•Cardiovascular Business
FDA Clears Elucid's AI-Driven FFR-CT Solution for Cardiac Imaging
Elucid's FFR-IQ, an AI-powered noninvasive FFR-CT tool, receives FDA clearance for clinical use.
•Radiology Business
FDA Approves SimBioSys AI Tool for Breast Cancer Risk via MRI
SimBioSys received FDA clearance for TumorSight Risk, an AI tool assessing breast cancer recurrence risk using MRI.